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Background: This study aims to validate the English version of the Pediatric Rheumatology Quality of Life Scale
(PRQL), a concise Health Related Quality of Life (HRQoL) measure, in a US cohort of children with juvenile idiopathic
arthritis (JIA).
Methods: The PRQL is a 10-item HRQoL measure with two subscales: physical health and psychological health. The
original version of this measure was validated using an Italian-speaking cohort of 472 JIA patients and 796 healthy
controls and found to have acceptable psychometric properties. The English language version has not been
validated in a US pediatric population. The English PRQL was administered to 161 JIA subjects from a US
Rheumatology clinic. We assessed the reliability (internal consistency and test-retest) and validity (convergent,
discriminative, and criterion) of the PRQL.
Results: The English PRQL was feasible to administer and demonstrated good psychometric properties. Cronbach
alpha (reliability) coefficients ranged from 0.72 to 0.81. Factor analysis yielded the existing subscales. The PRQL total
and subscales were found to have moderate correlations with other HRQoL instruments, the Pediatric Quality of
Life Inventory (PedsQL) generic core scale and the PedsQL rheumatology. The PRQL discriminated between
subjects with active versus inactive disease and was responsive to an improvement or worsening in disease activity
over time.
Conclusions: Our results suggest that the English version of the instrument is suitable for use in JIA patients in the
US. This tool provides a relatively easy method to integrate at least one patient-reported outcome into routine
clinical or research assessment.
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The importance of patient-reported outcomes (PROs),
reported by pediatric patients and their parents, is in-
creasingly emphasized in both routine clinic care and re-
search. PROs include items such as health related
quality of life (HRQoL), functional status, pain, and
satisfaction. Recently, the Consolidated Standards of
Reporting Trials (CONSORT) patient reported outcome
extension was released that urged inclusion of PROs as* Correspondence: weisspa@email.chop.edu
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reproduction in any medium, provided the orprimary or secondary outcomes in ancillary analyses for
all randomized controlled trials [1]. PROs are also im-
portant for high-quality patient centered care and com-
prehensive decision-making. HRQoL is a particularly
important PRO to include in the overall assessment of
children with juvenile idiopathic arthritis (JIA). If clinical
assessment is limited to physician-determined items
such as active joint count, the impact of factors such as
medication side effects, fear of injections, and missed
school for medication infusions may be overlooked.
Several validated HRQoL measures exist to measure
HRQoL in children with rheumatology conditions e.g. the
Pediatric Quality of Life Inventory (PedsQL) and the Juven-
ile Arthritis Quality of Life Questionnaire (JAQQ)), buttd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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costly, and/or complicated to administer in clinical settings.
The PedsQL has been validated and used extensively in a
wide range of diseases, including JIA [2-6]. However, the
PedsQL Generic Core contains 23 items and the PedsQL
Rheumatology Module contains 22 items, rendering them
cumbersome to complete during a clinic visit. Further, the
PedsQL Generic Core and Rheumatology modules are
costly to use in routine clinical practice [7]. The JAQQ is a
validated rheumatology specific measure that has also been
used in JIA and outcomes studies [8-11]. Similar to the
PedsQL it is time consuming to complete with 74 items.
The ability of children to select the 5 most problematic
areas in each domain to answer allows for a unique individ-
ualized assessment over time but makes comparison of
scores across children problematic [12].
The feasibility constraints of the previous HRQoL instru-
ments led to the development of the Pediatric Rheumatol-
ogy Quality of Life Scale (PRQL), a concise 10-item HRQoL
measure designed for use in the clinical setting but with po-
tential utility for research [13]. Items included in the PRQL
were derived from literature review, analysis of existing
HRQoL measures, study panel discussion, and face-to-face
interviews of children with rheumatic disease and their par-
ents. Two independent individuals translated the Italian ver-
sion of the PRQL to English [14]. Two native-English
translators then independently translated the English version
back to Italian. The translation was assessed by a focus
group of Pediatric Rheumatology International Trials
Organization (PRINTO) employees with translation expert-
ise to ensure the content of the instrument was preserved
across translation. The Italian version of PRQL was validated
using an Italian cohort of 472 JIA patients and 796 healthy
controls. The median age of JIA patients was 8.7 (IQR: 4.7,
12.2) years. The comparison group of healthy children had a
similar age distribution [13]. The PRQL possessed good
measurement properties, including feasibility and face, con-
tent, and construct validity, test-retest reliability, and good
responsiveness to patient improvement over time. A Cron-
bach’s α of 0.86 demonstrated good internal consistency.
The PRQL is available in English but has not been validated
in a US pediatric population [13].
The PRQL is an attractive option for use in routine clin-
ical practice because it is free, takes less than 5 minutes to
complete, and less than 1 minute to score. The aim of this
study was to validate the English PRQL in JIA subjects
from our US clinical practice, using the PedsQL (generic
core and rheumatology module) as the gold standard.
Methods
Human subjects protections
The protocol for the conduct of this study was reviewed
and approved by the Committee for the Protection of
Human Subjects.Subjects
The source population for the study was children with a
diagnosis of JIA who were 18 years of age or younger
and evaluated in the rheumatology clinic between
August 2011 and June 2012. Subjects were a conveni-
ence sample enrolled without regard to disease duration,
disease severity, current disease activity, or therapy. All
subjects met International League of Associations for
Rheumatology (ILAR) criteria [15] for JIA according to
the treating physician. 96% (161/167) of people
approached agreed to participate in the study.
Clinical data
The following demographics and clinical characteristics
were collected at the study visit: age, disease duration,
sex, race, and ILAR category.
Measures
Quality of life
The PRQL, PedsQL generic scale (version 4.0), and the
PedsQL-Rheumatology module (version 3.0) were com-
pleted by the parent(s)/legal guardian(s) or by the partici-
pant if 13 to 18 years old.
The PRQL is a concise 10-item QOL measurement that
uses 4-point Likert scales from 0 (never) to 3 (all the time).
Items are grouped into 2 subscales, physical health (PhH)
and psychosocial health (PsH). The total score ranges from
0 to 30, where higher scores indicate worse HRQoL. If
more than 2 questions are not answered in each sub-
domain, the PRQL score is not computed [13].
The PedsQL has been validated and used extensively in a
wide range of diseases, including JIA [2-6]. The PedsQL
has a validated rheumatology module for use among pa-
tients with JIA [6]. The PedsQL Generic Core contains 23
items, and the PedsQL Rheumatology Module contains 22
items. Both the generic and rheumatology questionnaires
use 5-point Likert scales from 0 (never) to 4 (almost al-
ways). Scores are transformed on a scale from 0 to 100,
where higher scores indicate better HRQoL.
Pain intensity
At enrollment the subject or parent was asked, “How
much pain have you [or your child] had because of your
[his/her] rheumatic condition in the past week?” Pain in-
tensity was reported using integers from 0 to 10, an-
chored by the words “No Pain” and “Very Severe Pain”.
High correlation between the traditional 10-centimeter
visual analogue scale (VAS) and the integer-based scale
has been reported for the measurement of pain intensity
[16-18].
Physical function
Subjects or parents rated the subject’s disease-related func-
tional status during the past week using the Childhood
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ity index (DI) is calculated based on the mean of the 8 do-
mains; the DI ranges from 0 to 3, with higher scores
indicating worse disability [20].
Parent/subject global health status
At enrollment the subject or parent was asked, “Consid-
ering all the ways that arthritis affects you/your child,
how do you rate how he/she is doing in the past week?”
Status was reported using integers from 0 to 10, an-
chored by the words “Very well” and “Very poor”.
Disease activity
A physician disease activity VAS was reported for each
visit using integers from 0 to 10. Physicians also deter-
mined whether subjects met criteria for inactive disease
according to the ACR provisional criteria [21]. Subjects
who did not fulfill these criteria were considered as hav-
ing active disease.
Data collection
Study data were managed using Research Electronic
Data Capture (REDCap) tools hosted at Children’s
Hospital of Philadelphia [22].
Procedure
In order to assess test-retest reliability, a small subset of
subjects were asked to retake the PRQL. Forty-three en-
rolled subjects or parents were emailed a copy of the
PRQL one week after the initial administration of the
questionnaire. A period of one week was used, as it is
not too short that respondents will not remember their
first response and not too long that the patients’ HRQoL
will have changed [23].
Analysis
We assessed the validity of the English version of the
PRQL using the Outcome Measures in Rheumatoid
Arthritis Clinical Trials (OMERACT) filter [24]. The
OMERACT filter was developed to simplify and
standardize the terminology used in rheumatology out-
come and validation studies.
Internal consistency reliability
Internal consistency was determined using Cronbach’s
alpha coefficient. Estimates greater than or equal to 0.70
were considered acceptable.
Test-retest reliability
Test-retest reliability was assessed using the intraclass
correlation coefficient (ICC) for total and both subscale
scores.Confirmatory factor analysis
Factor analysis is used to identify over-arching factors
that account for the common variance in the observed
PRQL items, excluding item-specific (unique) variance
[25]. We used confirmatory factor analysis (CFA which
is a type of factor analysis,) to test how well the 2-factor
model obtained for the Italian version of the instrument
fit our data. CFA was conducted since this instrument’s
factor structure is already known from previous re-
search. A Bentler’s Comparative Fit Index (CFI) > 0.9,
Bentler & Bonnett’s Non-Normed Fit Index (NNI) > 0.9,
and the root mean square error of approximation
(RMSEA) < 0.1 were considered indicative of an accept-
able model fit [26].
Post-hoc exploratory factor analysis
A post-hoc exploratory factor analysis of the PRQL was
also performed to check if the two-factor model fit
would be confirmed without making assumptions about
the data. We performed a common factor analysis,
which is more suitable for identifying latent factors than
principal components analysis. A maximum likelihood
factor analysis was performed in which squared multiple
correlations were used for the initial commonality esti-
mates. A promax (oblique) rotation was used to identify
the underlying factor structure.
Convergent and discriminative validity
Convergent validity of the candidate index was tested
using the PedsQL 4.0 generic scale integrated with the
PedsQL-Rheumatology 3.0 module as the gold standard.
We used two methods to assess correspondence be-
tween the two standardized measures: 1) Spearman’s
correlation, and 2) the method of Bland and Altman
[27]. The latter method evaluates the distribution of the
differences and plots them against the standardized
mean of the two measures.
Discriminative validity was evaluated by comparing
median PRQL scores between subjects with physician-
determined inactive disease (physician VAS of 0) versus
active disease (physician VAS≥1), using a Wilcoxon rank
sum test.
Responsiveness to change
Responsiveness of the PRQL to clinical change over time
was tested in subjects with a follow-up visit 3–7 months
after the initial study visit. We compared the mean
change in PRQL between visits in subjects who had an
improvement or worsening in disease activity according
to the treating physician using a two-tailed t-test and the
standardized response mean (SRM). The SRM is the
mean PRQL score divided by the standard deviation of
that score change [28]. SRMs were adjusted for the cor-
relation between the 2 PRQL measurements in order to
Table 1 Demographics
N (%)
Age at visit, years (median, IQR) 11.6 (7.2, 15.5)






Pacific Islander 2 (1)





Oligoarticular, persistent 44 (27)
Oligoarticular, extended 12 (7)
Polyarticular, RF-negative 36 (22)




Physician disease activity VAS (median, IQR) 0 (0,1)
Physician-defined status
Active disease 43 (27)
Inactive disease, on medication < 6 months 26 (16)
Clinical remission while on medication 53 (34)
Clinical remission, off medication <12 months 17 (11)
Clinical remission, off medication >12 months 19 (12)
Subject/parent global health status VAS 1 (0, 3)
Subject/parent pain VAS 1 (0, 4)
Legend: IQR= interquartile range, RF= rheumatoid factor,
PsA= psoriatic arthritis, ERA= Enthesitis-related arthritis.
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During the 10-month period we enrolled 161 children
with JIA. Demographic and clinical characteristics are
presented in Table 1. The most common JIA subtypes
were persistent oligoarticular (N = 44, 27%) and RF-
negative polyarticular (N = 36, 22%). Of those with avail-
able results 59 (37%) were ANA-positive, 7 (4%) were
RF-positive, and 17 (11%) were HLA-B27 positive. This
cohort had relatively low disease activity as measured by
the physician VAS and subject/parent global health sta-
tus VAS, and only 27% of subjects had active disease ac-
cording to the ACR provisional criteria [21].
Administration
The PRQL was simple for subjects and parents to com-
prehend. Completion of the PRQL required less than
5 minutes. Scoring of the questionnaire was straightfor-
ward and took less than 1 minute.
Descriptive statistics
All PRQL items, including their psychometric properties,
are shown in Table 2. Missing data was minimal (close
to 5%) and considered to be missing completely at
random.
Internal consistency reliability
Cronbach’s α was 0.81, 0.72, and 0.78 for the total score,
PhH subscale and PsH subscale, demonstrating good in-
ternal consistency. Cronbach’s α for the PRQL total
score and subscales among the following respondent
subgroups were equal to or greater than 0.70: males, fe-
males, inactive disease, and active disease.
Test-retest reliability
Forty-three enrolled subjects or parents were emailed a
copy of the PRQL one week after the initial administra-
tion of the questionnaire. The average time between
questionnaire completions was 11 days (IQR: 7,15). The
pairwise correlation coefficient and ICC for test-retest
reliability were 0.72 and 0.68, respectively, thereby dem-
onstrating adequate reliability.
Factor analysis
A two-factor model adequately fit the data (CFI = 0.93;
NNI = 0.91; RMSEA = 0.075). Post-hoc exploratory fac-
tor analysis, to check if a two-factor model would suit-
ably fit the data if no assumptions were made about thedata, provided further support for the two-factor struc-
ture (Figure 1).
Convergent validity
We used two methods to assess correspondence be-
tween the PRQL and an established measure of HRQoL
in JIA, the PedsQL generic core scale and the PedsQL
rheumatology module: 1) Spearman’s correlation, and 2)
the method of Bland and Altman [27]. The total PRQL
score was highly correlated with the total PedsQL gen-
eric score and moderately correlated with 4 out of 5 of
the PedsQL Rheumatology items (Table 3). The PRQL
subscales PhH and PsH were also moderately correlated
with the total PedsQL. The PhH correlated with the
PedsQL Rheumatology items better than the PsH.
Table 2 Pediatric rheumatology quality of life scale





Total score 2.60 3.02 1.45 (97) 60.2
Physical health subscale 1.55 1.76 1.41 (91) 56.5 0.85
Item 1: Been limited in taking care of him/herself, that is, eating, dressing, or washing him/
herself?
0.09 0.31 3.55 (12) 7.5 0.32
Item 2: Been limited in walking one block or climbing one flight of stairs? 0.21 0.44 1.96 (28) 17.4 0.55
Item 3: Been limited in doing activities that take a lot of energy, such as running, playing
soccer, or dancing?
0.40 0.63 1.46 (49) 30.4 0.66
Item 4: Been limited in doing schoolwork or activities with friends? 0.17 0.40 2.06 (24) 17.9 0.68
Item 5: Had bodily discomfort? 0.69 0.70 0.86 (85) 52.8 0.68
Psychosocial health subscale 1.12 1.81 1.78 (60) 37.3 0.85
Item 6: Felt sad or blue? 0.27 0.50 1.65 (36) 22.4 0.71
Item 7: Felt anxious or acted nervous? 0.26 0.49 1.61 (35) 21.7 0.69
Item 8: Had troubles getting along with other children? 0.09 0.31 3.60 (12) 7.5 0.39
Item 9: Had difficulty concentrating or paying attention? 0.26 0.60 2.55 (28) 17.4 0.64
Item 10: Felt dissatisfied about his/her looks or abilities? 0.24 0.58 2.69 (26) 16.2 0.69
Legend: Each item was prefaced by the phrase: “Considering the part 4 weeks, how often has your child…”.































-.2 0 .2 .4 .6 .8
Factor 2
Figure 1 Factor identification. Questions 1–10 (see Table 2) of the PRQL loaded on two factors after promax rotation. Questions 1–5 have
significant loadings (>0.30) on the factor “psychosocial health,” whereas questions 6–10 have significant loadings on the factor “physical health.”
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Table 3 Correlation between PRQL scores and the PedsQL






Total score 0.75* 0.65+ 0.62+
Psychosocial health 0.66+ 0.51+ 0.65+
Physical health 0.71* 0.71* 0.45+
Rheumatology module
Pain and hurt 0.69+ 0.73* 0.41+
Daily activities 0.52+ 0.52+ 0.37
Treatment 0.34 0.34 0.24
Worry 0.44+ 0.43+ 0.35
Communication 0.42+ 0.42+ 0.30
Parent/patient global health status VAS 0.60+ 0.66+ 0.32
Parent/patient pain VAS 0.62+ 0.67+ 0.35
Active joint count 0.13 0.15 0.11
Physician disease activity VAS 0.28 0.31 0.12
Legend: *high correlation defined as r>0.7; +Moderate correlation defined as
0.4>r<0.7; Poor correlation defined as ≤0.4.
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ity was also demonstrated using the Bland and Altman
method of agreement since the great majority of differ-
ences fall within 1.96 standard deviations of the mean
(Figure 2).
We also assessed the correspondence between the
PRQL and physician-determined disease activity and

































Figure 2 Bland-Altman plot showing correspondence between PedsQ
the mean indicate substantial agreement and evidence of convergent validmoderately correlated with the parent’s assessment of
global health status and pain. Correlations of the PRQL,
PhH, and PsH and the active joint count and physician-
determined disease activity were low. Correlations of the
PedsQL total, physical health, and psychosocial health
scores and the physician-determined disease activity
were similarly low (0.32, 0.37, and 0.21, respectively).Discriminative validity
Discriminative validity was evaluated using physician
disease activity VAS as the external criterion. Children
with a physician disease activity VAS of 0 (N=89) and
those with a VAS equal to or greater than 1 (N=57) were
compared using a Wilcoxon rank sum test. The median
PRQL scores for children with a physician VAS of 0 and
≥1 were 1 (IQR: 1,3) and 3 (IQR: 1,5), respectively
(p-value <0.001).Responsiveness
One hundred thirty one subjects had a PRQL recorded
at a follow-up visit a median of 4.5 months (IQR: 3.0 to
6.4) after the baseline visit. Ninety subjects had stable
disease activity, 22 improved, and 19 were worse accord-
ing to the treating physician. Using the t-test the mean
changes in PRQL scores were significantly different be-
tween those who improved and worsened according to
physician assessment (p<0.01), demonstrating good re-
sponsiveness (Figure 3). The PRQL total score SRMs for
those subjects who improved and worsened were 0.30



























-5 -4 -3 -2 -1 0 1 2 3 4 5
Mean change in PRQL between visits
95% CI Mean
Figure 3 Responsiveness of PRQL. The difference in mean changes in PRQL scores between those who had improved and worsened disease
activity were statistically significant by two-tailed t-test (p<0.01).
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The PRQL is a concise 10-item assessment of HRQoL
that was created primarily for use in clinical practice.
This prospective study supports the validity of this
HRQoL assessment in JIA patients in our US clinical
practice. Using cross-sectional data from 161 JIA sub-
jects we have shown evidence of feasibility, convergent
validity, discriminative validity, internal consistency, test-
retest ability, and responsiveness. Content validity of the
English PRQL was established prior to this study. The
Italian PRQL was found to have strong content and face
validity [13]. The Italian version was carefully forward-
and back-translated to preserve the content of the in-
strument and observe any difficulties or problems with
the translation. The rigorousness of the translation and
testing of the translated version provide support for the
content validity of the English version of the PRQL.
Interestingly the correlations between the PRQL and the
active joint count and physician disease activity VAS
were low. Correlation between the PedsQL and phys-
ician disease activity VAS was similarly low. While these
measurements assess different constructs of disease, one
might expect that active disease greatly affects HRQoL,
albeit not in a linear fashion. These findings highlight
the importance of collecting PROs both in clinical prac-
tice and registries as they provide different qualitative
information.
The brevity of this assessment tool makes it a feasible
and non-onerous measure to collect and score as part of
routine clinical practice. The limited number of items
does not cover the breadth of other HRQoL assessments
available for use in pediatric rheumatology including the
PedsQL and JAQQ. However, we have shown moderatecorrelation with at least one of these measures, the
PedsQL, by two different methods. For clinicians who
aspire to collect PROs but do not have the luxury of
time to administer, score, or pay for the PedsQL and/or
JAQQ the PRQL is a reasonable alternative.
Our findings should be interpreted in the context of
several limitations. First the validity assessment was con-
fined to JIA patients and did not include other rheuma-
tologic conditions. The validity of this measurement tool
in other pediatric rheumatology conditions should be ex-
plored in future analyses. Second, our study population
was a convenience sample of JIA subjects; however, they
were recruited without regard to disease duration, dis-
ease severity, current disease activity, or therapy. Disease
attributes may have differed in children who were and
were not enrolled in this study; however, we expect that
any selection bias would be non-differential in regards
to this validity analysis.
Conclusions
Despite caveats, our study indicates the PRQL is a valid
tool for the assessment of HRQoL in children and ado-
lescents with JIA in our US practice. Further it is easy to
administer, simple and quick to complete, and takes
minimal time and effort to score. This tool provides a
relatively easy method to integrate PROs into routine
clinical assessment and research.
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